Document Detail


Carvedilol, a novel cardiovascular agent, inhibits development of vascular and ventricular hypertrophy in spontaneously hypertensive rats.
MedLine Citation:
PMID:  8193608     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effects of carvedilol, a novel cardiovascular agent, were evaluated in developing spontaneously hypertensive rats (SHR) for effects on hemodynamics, and the ability to effect the development of left ventricular, and vascular hypertrophy associated with chronic hypertension. Chronic oral administration of low dose carvedilol (20 mg/kg/day) was initiated when rats were 5 weeks of age, and experiments progressed until 14 weeks of age. Carvedilol-treated SHR had significantly reduced systolic blood pressures and heart rates throughout the duration of the experiment, and had significantly reduced ventricle/body weights by approximately 9.0%. Morphologic analysis of tertiary branches of the mesenteric artery revealed that carvedilol-treated SHR had significant reductions in medial cross-sectional area. Carvedilol produced concentration-dependent inhibition of basal [3H]thymidine incorporation in cultured SHR vascular smooth muscle cells, as well as by stimulation produced by PDGF (1 nM), EDGF (1 nM), thrombin (0.5 U/ml), or endothelin-1 (1 nM), indicating that carvedilol had direct anti-mitogenic activity. The present studies demonstrate that low dose carvedilol produced sustained reductions in blood pressure and heart rate in developing SHR that were accompanied by significant inhibition in the development of vascular and myocardial hypertrophy. The morphological changes induced by carvedilol may be mediated by a combination of hemodynamic effects, as well as by direct anti-mitogenic effects on vascular smooth muscle.
Authors:
E H Ohlstein; L Vickery; A Arleth; F Barone; C P Sung; A Camden; L McCartney
Related Documents :
11751728 - Pulse pressure, endothelium function, and arterial stiffness in spontaneously hypertens...
18075218 - Interaction between alpha-linolenic acid-enriched oil and ace inhibitor concerning the ...
6083408 - Resistance vessel abnormalities in spontaneously hypertensive rats.
2396678 - Tubuloglomerular feedback kinetics in spontaneously hypertensive and wistar-kyoto rats.
3807468 - A contribution to indirect ophthalmotonometry in beagles.
20424958 - Sodium sensitivity of blood pressure in chinese populations.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical and experimental hypertension (New York, N.Y. : 1993)     Volume:  16     ISSN:  1064-1963     ISO Abbreviation:  Clin. Exp. Hypertens.     Publication Date:  1994 Mar 
Date Detail:
Created Date:  1994-06-30     Completed Date:  1994-06-30     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9305929     Medline TA:  Clin Exp Hypertens     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  163-77     Citation Subset:  IM    
Affiliation:
Department of Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406-0939.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Animals
Antihypertensive Agents / pharmacology
Aorta / metabolism,  pathology
Blood Vessels / drug effects*
Carbazoles / pharmacology*
Cardiomegaly / prevention & control*
DNA / biosynthesis
Dose-Response Relationship, Drug
Heart Ventricles
Male
Mesenteric Arteries / drug effects,  pathology
Muscle, Smooth, Vascular / metabolism,  pathology
Propanolamines / pharmacology*
Rats
Rats, Inbred SHR
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Carbazoles; 0/Propanolamines; 0K47UL67F2/carvedilol; 9007-49-2/DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mineralocorticoid induced hypertension and noradrenaline spillover in man.
Next Document:  Evaluation of cilazapril versus captopril in patients with mild to moderate essential hypertension.